Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

hypereosinophilic syndrome (HES) - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

hypereosinophilic syndrome

MONDO:0015691

Also known as:HESeosinophilic leukocytosiseosinophilia

Find Clinical TrialsTrials

Overview

Hypereosinophilic syndrome (HES) constitutes a rare and heterogeneous group of disorders, defined as persistent and marked blood eosinophilia and/or tissue eosinophilia associated with a wide range of clinical manifestations reflecting eosinophil-induced tissue/organ damage.

Treatments1 FDA approved

Clinical Trials13 registered · 7 recruiting

Diagnosis

Biomarker and diagnostic research for hypereosinophilic syndrome has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for hypereosinophilic syndrome, including MEPOLIZUMAB (NUCALA, approved 2015). An additional 2 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

13 clinical trials registered, 7 recruiting. Interventions under study include other interventions, drug therapy, biologic therapy, and procedural interventions. Pipeline includes 1 PHASE4, 3 PHASE3, 3 PHASE2. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT07275190](https://clinicaltrials.gov/study/NCT07275190)

Data assembled from 5 of 12 sources · Last updated Oct 4, 2026, 2:41 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:168956

GARD

Genetic and Rare Diseases Info Center

GARD:2804

Questions for Your Care Team

→What are the benefits and potential side effects of NUCALA for managing hypereosinophilic syndrome?
→Are any of the 13 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
benralizumab	benralizumab	AstraZeneca Pharmaceuticals LP	2019	—	Designated
reslizumab	reslizumab	Teva Respiratory, LLC	2011	—	Withdrawn

Research Type	Count	% of Total
Patient case studies	118	52%
Research summaries	37	16%
Disease patterns and progression	19	8%
Clinical study results	16	7%
Laboratory research	13	6%
Other research	10	4%
Testing and diagnosis research	9	4%
New treatment approaches	5	2%

Kisho

hypereosinophilic syndrome

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Sustained low disease activity during long-term mepolizumab treatment in FIP1L1::PDGFRA-negative hypereosinophilic syndrome: a multicenter real-world study.

Incidence and prevalence of hypereosinophilic syndrome in the United States: A retrospective claims database study.

Ruxolitinib for life-threatening corticosteroid-refractory hypereosinophilic syndrome: A multicenter case series.

hypereosinophilic syndrome

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Sustained low disease activity during long-term mepolizumab treatment in FIP1L1::PDGFRA-negative hypereosinophilic syndrome: a multicenter real-world study.

Incidence and prevalence of hypereosinophilic syndrome in the United States: A retrospective claims database study.

Ruxolitinib for life-threatening corticosteroid-refractory hypereosinophilic syndrome: A multicenter case series.